

## Special Issue

# Avian Influenza Virus: New Strategies to Elicit Immune Responses and to Prevent and Control Infection

### Message from the Guest Editor

Avian influenza virus infection (AIV) has spread worldwide spread, and is a highly contagious. AIV infection is one of the greatest causes for recent concerns to public health and the economy worldwide. AIV has been considered to be one of the most high-priority pathogens and an economically important poultry virus. Despite the extensive research in recent decades to improve vaccine efficacies, surveillance methods, and biosecurity measures to control viral respiratory infections in poultry, recent outbreaks of AIVs have provoked notable concerns about the available measures and resources for controlling the spread of the virus and preventing disease. Due to the importance of public health concerns of avian influenza virus and its potential economic consequences, we would like to present this Special Issue documenting the recent progress in understanding of host–virus interactions and research efforts focused on developing effective vaccines and prophylactic strategies as well as novel approaches to tailor favorable host antiviral responses to control diseases that are caused by AIV.

---

### Guest Editor

Dr. Neda Barjesteh

Department of Pathology and Microbiology, Faculty of Veterinary Medicine, University of Montreal, Montreal, Canada

---

### Deadline for manuscript submissions

closed (31 July 2021)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/40961](https://mdpi.com/si/40961)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).